Modeling Pancreatic Cancer through Somatic Editing with AAV

Alvaro Curiel-GarcÍa; Kenneth P Olive

doi:10.1016/j.molmed.2019.02.012

Modeling Pancreatic Cancer through Somatic Editing with AAV

Trends Mol Med. 2019 May;25(5):361-362. doi: 10.1016/j.molmed.2019.02.012. Epub 2019 Mar 13.

Authors

Alvaro Curiel-GarcÍa¹, Kenneth P Olive²

Affiliations

¹ Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
² Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA. Electronic address: kenolive@columbia.edu.

PMID: 30878400
DOI: 10.1016/j.molmed.2019.02.012

Abstract

Genetically engineered mouse models have revolutionized the study of pancreatic cancer, but have several technical and practical limitations. A new adeno-associated virus (AAV)-driven somatic genome-editing model of pancreatic ductal adenocarcinoma reported by Ideno et al. (Lab. Invest. published online February 6, 2019; https://doi.org/10.1038/s41374-018-0171-z) addresses several of these limitations, achieving rapid and penetrant induction of multiple targeted alterations in the adult murine pancreas.

Keywords: CRISPR/Cas9; cancer; in vivo; pancreas; pancreatic cancer; somatic genome editing.

Publication types

Letter

MeSH terms

Animals
Biomarkers, Tumor
Carcinoma, Pancreatic Ductal / etiology
Carcinoma, Pancreatic Ductal / metabolism
Carcinoma, Pancreatic Ductal / pathology
Dependovirus / genetics*
Gene Editing* / methods
Genetic Association Studies*
Genetic Predisposition to Disease*
Genetic Vectors / genetics*
Humans
Mice
Pancreatic Neoplasms / etiology*
Pancreatic Neoplasms / metabolism
Pancreatic Neoplasms / pathology

Substances

Biomarkers, Tumor